

an Open Access Journal by MDPI

Cancer Epigenetic Biomarkers

Guest Editor:

Prof. Dr. Fabio Coppedè

Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions:

closed (20 May 2023)

Message from the Guest Editor

Cancer represents one of the most threatening human diseases, with millions of diagnosed novel cases and deaths occurring worldwide every year. The global aging of the population and the increased exposure to environmental carcinogens, coupled with the adoption of lifestyle behaviors such as smoking, poor diets, and scarce physical activity, account for the majority of cancers in both developed and less-developed countries.


It is also well ascertained that genetic, epigenetic, and cytogenetic modifications occur within cancer cells and tissue, many of which are driven by environmental exposures and are responsible for the acquisition of the malignant phenotype. Particularly, it is now clear that hundreds of genes change their expression in the multistep process of carcinogenesis as a consequence of epigenetic events, including promoter hypermethylation, histone-tail modifications, chromatin remodeling, or interference mechanisms mediated by non-coding RNA molecules.

This Special Issue will focus on the most recent advances in cancer epigenetics, as well as on the discovery and utility of cancer epigenetic biomarkers.



mdpi.com/si/95112

Special Issue



Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[@Cancers_MDPI](https://twitter.com/Cancers_MDPI)